Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 29;129(3):551–562. doi: 10.1038/s41416-023-02319-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a The schematic representation of the experimental design. Male BALB/c nude mice (6–8 weeks old) were injected intraperitoneally with 1 × 10⁶ MKN45-Luc cells/each, and seven days later groups were treated with PBS, 1 × 10⁷ cells/100ul per mouse HG-CAR-PMs cells; low-dose 1 × 10⁶, medium-dose 1 × 10⁷ and high-dose 1 × 10⁸ HF-CAR-PMs cells/100 μL per mouse for the HF-CAR-PMs treatment groups. b, c Representative image and quantitative analysis of tumour weight in the vehicle, HG-CAR-PMs, and HF-CAR-PMs treatment groups. d Quantitative analysis of spleen weight for the vehicle, HG-CAR-PMs, and HF-CAR-PMs treatment groups. e Quantitative analysis of fluorescence intensity captured every 7 days for each group. Tumour-bearing mice were injected intraperitoneally with 2 mg of luciferase substrate solution each (Fluorescence intensity range 8 × 10⁷–2 × 10⁹). f Representative bioluminescence imaging and survival curve of each treatment group. Statistical analysis by one-way ANOVA with Tukey’s multiple comparison test. *P < 0.05, **P < 0.01 and ***P < 0.001.